FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OM	D /	חח		۸ / ۸
	IB 4	۱PP	ĸ.	WA

OMB Number:	3235-0287
Estimated average burde	n
hours per response:	0.5

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * OLUKOTUN ADEOYE Y			2. Issuer Name and Ticker or Trading Symbol <u>Tonix Pharmaceuticals Holding Corp.</u> [ TNXP ]		tionship of Reporting Person(s) all applicable)	s) to Issuer			
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 05/08/2023	A	Officer (give title below)	Other (specify below)			
C/O TONIX PHARMACEUTICALS HOLDING CORP 26 MAIN STREET, SUITE 101 (Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	Individual or Joint/Group Filing (Check Applicable Li     X Form filed by One Reporting Person     Form filed by More than One Reporting Person					
CHATHAM NJ 07928			Rule 10b5-1(c) Transaction Indication						
(City)	(State)	(Zip)	Check this box to indicate that a transaction was made pursuant to a contra affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.	act, instruction or written plan that is intended to satisfy the					

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	cution Date, Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect (I)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Code (In	Transaction Derivative Code (Instr. Securities		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative	9. Number of derivative Securities Beneficially Owned Following Reported	Form: Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)			
Stock Option	\$0.509	05/08/2023	A		60,000(2)		05/08/2024 <sup>(1)</sup>	05/08/2033	Common Stock	60,000(2)	<b>\$0.00</b> <sup>(1)</sup>	60,000	D		

### **Explanation of Responses:**

- 1. The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2024 Annual Meeting of Stockholders.
- 2. Does not reflect a 1-for-6.25 reverse stock split of the Issuer's common stock effective May 10, 2023.

/s/ Jessica Morris, Attorney-in-05/10/2023

Fact

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.